Latest Health News

Page 5 of 271
Impact Minerals is shifting decisively towards Lake Hope’s high-purity alumina project after raising A$2.21 million and changing its leadership structure. The company now has A$2.61 million in cash, but still faces the more difficult task of funding pilot work, feasibility studies and eventual project development.
Victor Sage
Victor Sage
30 Oct 2026
Adherium delivered a fifth consecutive quarterly record for remote patient monitoring revenue, but ended September with only A$120,000 in cash after a A$3.499 million operating outflow. Post-quarter loans and an AstraZeneca milestone payment have improved near-term liquidity, although further funding remains central to the company’s plans.
Victor Sage
Victor Sage
30 Oct 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.
Ada Torres
Ada Torres
30 Oct 2026
EZZ Life Science cut its quarterly operating cash outflow sharply despite a 37.7% drop in customer receipts, as weaker Chinese e-commerce sales continued to weigh. EAORON skincare growth and a $9.16 million cash balance offer some support, but distributor collections and potential product returns remain unresolved.
Victor Sage
Victor Sage
30 Oct 2026
Visionflex ended the September quarter with A$657,000 in cash and estimated funding for just 2.1 quarters, while aged care subscription losses drove a 25% fall in reported ARR. Revenue edged higher and costs improved, but the company now needs hardware wins to become recurring income before liquidity tightens further.
Victor Sage
Victor Sage
30 Oct 2026
Xenitra has returned to positive quarterly gross profit as its new pharmaceutical and Web3 businesses begin generating revenue, but statutory operating cash flow remained negative at A$790,000. The company is now relying on procurement targets, repeat Web3 sales and further capital discipline to turn early commercial activity into sustainable cash generation.
Victor Sage
Victor Sage
30 Oct 2026
Third Age Health lifted first-half revenue 20.8% and statutory profit 38.4% as aged medical care services supplied almost all of the growth. The NZX-listed healthcare provider maintained its 4 cents per share quarterly dividend while warning that cybersecurity and technology investment could weigh on near-term earnings.
Ada Torres
Ada Torres
30 Oct 2026
Kingsgate’s cash balance climbed to A$108.9 million despite a difficult September quarter at Chatree, where a 47-day mill shutdown, heavy rainfall and geotechnical constraints cut gold production. The company is relying on a stronger second half of FY27, insurance proceeds and longer-term growth at Nueva Esperanza to offset the near-term disruption.
Maxwell Dee
Maxwell Dee
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
HeraMED has moved its Lee Health digital maternity program from a six-month pilot into a paid deployment covering an initial 200 mothers. The milestone brings commercial revenue, but the company still faces a short cash runway as it works to scale the US rollout.
Victor Sage
Victor Sage
30 Oct 2026
McPherson’s has entered FY27 with first-quarter sales about 11% below the prior corresponding period, after a disappointing FY26 loss and a costly operating transition. The company says EBITDA growth remains achievable, but its transformation now faces a test of execution and leadership change.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive